Boston scientific research:
Boston Scientific: Category Leadership Meets the 2026 Reset — and a Decade of Runway in India and China Nobody Is Pricing
At roughly 14× adjusted 2026 earnings, the market is now pricing Boston Scientific like a company whose best days of growth are behind it. We think it is being asked the wrong question — not whether FARAPULSE and WATCHMAN can outrun better-funded competitors this year, but whether a category-leadership machine with barely any presence in the two largest cardiovascular-disease populations on Earth deserves a premium multiple once that gap starts closing.
We have watched Boston Scientific for over a year. We did not act on it while the market was paying up for perfection. We are interested now, at 14× earnings, because the price has finally moved to reflect doubt rather than certainty — and doubt is where our kind of opportunity lives. The question tomorrow's print has to answer is narrow: did the April guidance cut set a floor, or was it the first crack in a franchise that is losing share faster than the market has grasped? Everything else — including the growth story we think is genuinely underpriced — sits downstream of that answer.
"The more the market sells off, the more we are interested. Boston Scientific spent three years compounding organic growth from 12.3% to 15.8% while expanding margin every step of the way. The market has now priced that entire regime as unrepeatable. We do not think that bet is free."
— Muffett InvestmentsBoston Scientific's edge has never been one blockbuster device. It is a repeatable institutional capability: enter a procedure category, build the device that defines it, and use the installed base of implanting physicians to defend it for a decade. FARAPULSE in pulsed-field ablation, WATCHMAN in left-atrial-appendage closure, AGENT in drug-coated coronary balloons — all built on the same playbook. Cardiovascular is 66% of 2025 sales and grew organically 20.8%. Endoscopy, Urology and Neuromodulation are the diversification, and 2025 shows why the market still prices this as a Cardiovascular story first.
| Business | 2025 Sales | Organic Growth | Investment Role |
|---|---|---|---|
| Cardiovascular | $13.25B | 20.8% | Core growth engine — EP, WATCHMAN, coronary, vascular |
| Endoscopy | $2.92B | 7.7% | Durable procedure growth, innovation platform |
| Urology | $2.71B | 4.7% | Large installed base, currently the problem child |
| Neuromodulation | $1.20B | 8.0% | Smaller adjacency, improving momentum |
The diversification is real, but it is not yet load-bearing. If EP and WATCHMAN both slow at once, faster growth in the smaller franchises cannot immediately fill the gap — which is exactly what happened in Q1. That is the honest bear case, and we are not going to pretend it isn't sitting inside this thesis.
Before this year, Boston Scientific had built one of the best growth-and-margin combinations in large-cap medtech. That combination is why the stock traded at a persistent premium multiple, and why the multiple is now being tested.
From 2023 to 2025, organic growth accelerated from 12.3% to 15.8% while adjusted operating margin expanded from 26.3% to 28.0% and adjusted EPS rose from $2.05 to $3.06. That is the regime the market extrapolated — and the reset to 6.5–8.0% organic growth for 2026 is the market concluding it was unsustainable. Our view: the share-price decline already assumes the low end of that range is the new normal. The opportunity only exists if it is not.
FARAPULSE and electrophysiology. Pulsed-field ablation remains one of medtech's most important procedure-growth markets, and FARAPULSE still leads it — but Johnson & Johnson, Medtronic and Abbott are no longer standing still. Q1 EP sales were approximately $905 million, up ~24% reported; U.S. EP grew 18%, international EP roughly 30% operationally. The question is not whether EP is growing. It is whether it keeps growing above-market once share normalises against three well-funded competitors entering at once.
WATCHMAN. WATCHMAN created and scaled the left-atrial-appendage closure category outright. Q1 sales reached approximately $506 million, but procedure growth decelerated, and management named this franchise the primary reason for the full-year guidance cut. Watch procedure volumes and referral dynamics tomorrow before watch the headline EPS number.
Coronary and vascular. AGENT drug-coated balloon and the broader coronary portfolio are the offset the market is underweighting — complex PCI growth running through Boston Scientific's already-dominant interventional-cardiology channel.
This thesis survives if FARAPULSE stays a category leader even as competitors arrive, WATCHMAN returns to durable procedure growth, and AGENT keeps broadening the mix. Tomorrow's call has to address all three, not just beat the EPS line.
Endoscopy grew 6.8% organically in Q1 — solid, recurring, not enough on its own to offset a Cardiovascular slowdown. Neuromodulation grew a standout 15.4% but is still only ~$318 million a quarter, too small to move the group result. Urology is the actual problem: Q1 sales of ~$646 million on just 0.5% organic growth, against an installed base that was supposed to deliver dependable mid-single-digit growth every quarter. Boston Scientific needs Urology fixed because the balance sheet is about to be committed to another large Cardiovascular bet.
Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion enterprise value — roughly $11 billion cash/debt, ~$4 billion in stock — adding mechanical thrombectomy, embolisation and neurovascular capability to the same category-leadership playbook that built EP and WATCHMAN. At Q1 end, Boston Scientific already carried ~$10.9 billion of debt against $1.45 billion of cash. This deal does not just add a growth vector; it changes the risk profile of the whole company. Growth now has to be assessed alongside leverage and financing cost, not on its own.
| Strategic Benefit | Why It Matters | Principal Risk |
|---|---|---|
| Mechanical thrombectomy | Entry into large, underpenetrated vascular markets | Premium price, execution risk |
| Neurovascular | New physician relationships, new treatment categories | Integration outside the traditional core |
| International distribution | BSX can globalise Penumbra's products fast | Commercial disruption mid-integration |
| Cost synergies | Supply chain and operating leverage | Savings arrive later than promised |
Penumbra can extend the category-leadership model — but it also removes the margin for error. A weakening core business makes a $14.5 billion acquisition materially harder to digest, and that is precisely the scenario a soft print tomorrow would put on the table.
Every stock we look at closely gets the same question: what is the developing-world opportunity, and how early is it? For Boston Scientific, this is where the pre-earnings noise around FARAPULSE share loss and Urology softness gives way to a much bigger, much slower-moving number — global cardiovascular disease is concentrating in exactly the two countries where Boston Scientific has the least revenue relative to its addressable population.
South Asia holds roughly a quarter of the world's population and carries an estimated 60% of the global cardiovascular disease burden. In India specifically, cardiovascular disease now accounts for 14.1% of national disability-adjusted life years — roughly double its share in 1990 — and ischaemic heart disease and stroke case counts have risen 2.3× over the same period, against a population where the over-65 cohort is projected to reach 22.5% by 2051. This is not a speculative demographic story. It is a procedure-volume story that is already happening, in a market where interventional cardiology device spend is estimated to grow from roughly $318 million in 2024 to $656 million by 2033 — an 8.4% CAGR that starts from a base small enough that a single-digit percentage of Boston Scientific's global Cardiovascular revenue could dominate it.
Boston Scientific is not entering India cold. The company has run an R&D and engineering presence there since 2014 (Gurgaon), expanded with a second, larger centre in Pune in 2022, and partnered with Wipro GE Healthcare on cardiac-care initiatives the same year. None of that shows up as a line item — Boston Scientific does not break out India revenue in its filings, and it should not be treated as if it does. What we can say with confidence is the structural setup: a company with a proven category-creation playbook, an existing engineering foothold, and a domestic disease burden growing faster than almost anywhere else in the world. That is the definition of underpriced optionality, not a number we can put in a model yet.
China is the more complicated, but arguably more advanced, story. Volume-based procurement has been brutal on headline pricing — Boston Scientific's coronary stents were cut from roughly 17,000 yuan to 775 yuan, a 93% reduction, in China's first national tender in November 2020, and VBP has since extended into balloons, catheters and other consumables with 60–90% price cuts across categories. This is the China risk every medtech investor already knows. What gets less attention is the volume response on the other side of that pricing cut: China's population aged 60 and over stood at roughly 310 million in 2024 — about 22% of the country — growing more than 10 million a year and projected to exceed 400 million by 2035. Reported commentary from Boston Scientific's own Q1 2026 call described ongoing double-digit growth in China even through the pricing headwind, which is exactly the pattern you would expect if VBP is compressing price per procedure while procedure count is growing fast enough to more than offset it.
"China's VBP program is a margin story, not a growth-ceiling story. A government prepared to cut your price 90% on a stent is a government that has decided it wants every patient who needs one to get one. That is the trade: lower price per unit, dramatically larger addressable procedure volume. Boston Scientific has already been through the worst of the pricing adjustment. The volume side of that trade is still building."
— Muffett InvestmentsWe want to be precise about what this section is and is not. Boston Scientific does not disclose India or China revenue as standalone figures, and we have not found company guidance that quantifies either market's contribution to the 2026–2028 growth algorithm. This is optionality, not a modelled catalyst for tomorrow's print — the kind of thing that will not move a quarter, but that we think the market is not paying anything for in a stock trading at 14× earnings. If the 2026 reset holds and Penumbra integrates cleanly, India and China are the multi-year growth vectors that could justify a re-rating back toward the 18–22× multiples this business used to command — not because either market shows up in next quarter's guide, but because the demographic math behind them does not reverse.
| Metric | Original 2026 View | Reset 2026 View | Q2 Guide / Consensus |
|---|---|---|---|
| Organic sales growth | 10.0–11.0% | 6.5–8.0% | Company: 5.0–7.0% |
| Adjusted EPS | $3.43–$3.49 | $3.34–$3.41 | Company: $0.82–$0.84 |
| Q2 revenue | — | — | Consensus ~$5.39–$5.42B |
| Q2 adjusted EPS | — | — | Consensus ~$0.83 |
Management attributed the reset primarily to WATCHMAN pressure, faster-than-expected EP share erosion, and weaker Urology. That specificity is a gift for tomorrow's analysis — it names exactly the three things that have to stop deteriorating for the reset to be the floor rather than the start of a slide.
On 27 July, Boston Scientific disclosed a new global restructuring programme — supply-chain optimisation, manufacturing transfers, organisational change — expecting $700–800 million of pre-tax costs and roughly $500 million of annual expense reduction once substantially complete by end-2029.
| Question | Constructive Read | Cautious Read |
|---|---|---|
| Why now? | Scale requires a more efficient global footprint | Growth slowdown forced a cost response |
| $500M savings | Supports margin and reinvestment capacity | Much gets reinvested, limiting EPS flow-through |
| Manufacturing moves | Supply-chain resilience, productivity | Execution and service-level disruption risk |
| Job reductions | Resources shift to priority growth areas | Morale and commercial disruption risk |
This is positive if it preserves innovation while simplifying the cost base. It is negative if it becomes the mechanism used to defend earnings while organic growth keeps weakening underneath it.
At $47.03 on 28 July, Boston Scientific trades at roughly 13.9× the midpoint of adjusted 2026 EPS guidance ($3.375). We do not chase high multiples, and we are not starting to here either — the valuation is the reason this is on the list, not a target we're calling in isolation.
| Scenario | 2026 Adj. EPS | Illustrative P/E | Illustrative Value | What Must Be True |
|---|---|---|---|---|
| Bear | $3.25 | 12× | $39 | Further guide cut; EP/WATCHMAN pressure persists |
| Base | $3.38 | 15× | $51 | Reset holds; organic growth stabilises |
| Recovery | $3.45 | 18× | $62 | Beat-and-raise; confidence in the 2027 rebuild |
| Bull | $3.55 | 22× | $78 | Share stabilises, margins expand, Penumbra de-risks, India/China optionality starts getting priced |
These are scenario tools, not price targets to trade against. The multiple should follow evidence, and a higher one is only justified once tomorrow improves confidence in the 2027–28 earnings path — not before.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Organic growth | >7% or strong mix | 5–7% | <5% |
| Adjusted EPS | >$0.84 with quality | $0.82–0.84 | <$0.82 |
| 2026 guidance | Raised / upper-half confidence | Reiterated | Cut again |
| U.S. EP | Share stabilisation | Growth, continued pressure | Accelerating share loss |
| WATCHMAN | Procedure reacceleration | Stable but soft | Further deceleration |
| Urology | Clear recovery evidence | Low-single-digit growth | Flat / negative |
| Adjusted margin | Expansion despite reinvestment | On plan | Cost pressure |
| Penumbra | Timeline, financing de-risked | No change | Delay / higher financing risk |
Questions we'd want answered on the call:
What is the current U.S. FARAPULSE market-share trajectory, and where does management expect it to stabilise?
Is WATCHMAN weakness procedural timing, referral friction, reimbursement, or straight competition?
What is actually being done to fix Urology, and on what timeline?
How much of the $500M restructuring saving is reinvested versus retained as operating profit?
Does Penumbra financing or regulatory review change the expected close or leverage path?
Is there any update — even directional — on India or China as standalone growth contributors?
| Thesis Confirmation | Thesis Breaker |
|---|---|
| EP growth stays above-market, share erosion moderates | FARAPULSE loses share faster despite market growth |
| WATCHMAN procedure growth reaccelerates | Persistent deceleration or pricing pressure |
| Urology returns to mid-single-digit growth | Flat growth becomes structural |
| Organic growth holds above the revised range midpoint | A second consecutive guidance cut |
| Restructuring improves productivity without hurting innovation | Savings mask weaker revenue or service disruption |
| Penumbra closes on manageable financing terms | Delay, integration stress, or excessive leverage |
| Company | Trailing P/E | Forward P/E | Market Cap | Price / Sales |
|---|---|---|---|---|
| Boston Scientific (BSX) | 19.48 | 13.18 | $69.01B | 3.21× |
| Medtronic (MDT) | 21.99 | 13.76 | $106.51B | 2.90× |
| Abbott Laboratories (ABT) | 33.35 | 18.69 | $179.51B | 3.86× |
| Stryker Corporation (SYK) | 38.22 | 22.03 | $126.60B | 5.05× |
Boston Scientific trades at the lowest forward multiple in its peer set despite having posted the fastest organic growth of the four through 2025. Even giving full weight to the 2026 reset, that gap is the market's clearest statement yet that it does not believe the growth premium survives — which is exactly the assumption tomorrow's print gets to test.
We are constructive, not maximally bullish, going into tomorrow. The valuation now allows for disappointment — that is the whole reason this is interesting at 14× instead of 20× — but the evidence has to show the April reset was conservative, not merely accurate. A small EPS beat without improving franchise commentary on EP, WATCHMAN and Urology would not be enough for us.
What keeps us engaged beyond tomorrow's number is the part of this business that isn't in any consensus model: a category-leadership machine with a real, if still early, foothold in India and a China business that has already absorbed the worst of VBP pricing and is compounding on volume anyway. Neither shows up in Q2 guidance. Both sit on top of the two largest and fastest-growing cardiovascular-disease populations in the world. We size accordingly — a half position building toward a full one if the reset holds — and we are entirely comfortable adding into further weakness if the thesis stays intact, because that is precisely the setup we look for: a scaled compounder, a market that has stopped paying for growth, and a demographic tailwind measured in decades, not quarters.
This document is independent research prepared by Muffett Investments for informational and educational purposes only. It does not constitute investment advice. Past performance is not indicative of future results. Capital is at risk.
